A large number of novel therapeutics is currently undergoing clinical evaluation for the
treatment of prostate cancer, and small molecule signal transduction inhibitors are a …

Background Despite significant advances in molecular characterization and therapeutic
targeting of advanced prostate cancer, it remains the second most common cause of cancer …

Although the prognosis of patients with localized prostate cancer is good after surgery, with
a favorable response to androgen deprivation therapy, about one third of them invariably …

The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of
the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the …

Prostate cancer (PCa) is the second most common malignancy among men in the world.
Castration-resistant prostate cancer (CRPC) is the lethal form of the disease, which …

Prostate cancer remains a major cause of cancer-related mortality. Genetic clues to the
molecular pathways driving the most aggressive forms of prostate cancer have been limited …

Abstract The PI3K/Akt pathway is an actively pursued therapeutic target in oncology. In
prostate cancer, the activation of this pathway appears to be characteristic of many …

Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

The PI3K signaling pathway is activated in a majority of cancer types. It promotes
tumorigenesis by regulating nutrient metabolism, cell proliferation, survival, migration, and …

Despite recent advances in our understanding of the biological basis of prostate cancer, the
management of the disease, especially in the castration-resistant phase, remains a …